

AD-A033 511

ARMED FORCES RADIOBIOLOGY RESEARCH INST BETHESDA MD
SUPPRESSION BY 1,3-BUTANEDIOL OF THE ETHANOL WITHDRAWAL SYNDROM--ETC(U)
JUL 76 E MAJCHROWICZ, W A HUNT, C PIANTADOSI
AFRRI-SR76-38

F/6 6/1

UNCLASSIFIED

NL


1 OF 1
AD
A033511



END

DATE
FILMED
2-77

ADA033511



UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER AFRRI-SR76-38	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) SUPPRESSION BY 1,3-BUTANEDIOL OF THE ETHANOL WITHDRAWAL SYNDROME IN RATS	5. TYPE OF REPORT & PERIOD COVERED Scientific rept.	
7. AUTHOR(s) E. Majchrowicz, W. A. Hunt, C. Piantadosi (*National Institute on Alcohol Abuse and Alcoholism, †University of North Carolina)	6. CONTRACT OR GRANT NUMBER(s)	
9. PERFORMING ORGANIZATION NAME AND ADDRESS Armed Forces Radiobiology Research Institute Defense Nuclear Agency (AFRRI) Bethesda, Maryland 20014	10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS NWED QAXM C 912 18	
11. CONTROLLING OFFICE NAME AND ADDRESS Director Defense Nuclear Agency (DNA) Washington, D. C. 20305	12. REPORT DATE July 1976	
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)	13. NUMBER OF PAGES 15	
12 14p.	15. SECURITY CLASS. (of this report) UNCLASSIFIED	
16. DISTRIBUTION STATEMENT (of this Report) Approved for public release; distribution unlimited		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number)		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number) 1,3-Butanediol (BD) was tested for its ability to suppress an ethanol withdrawal syndrome. Male Sprague-Dawley rats were rendered physically dependent upon ethanol by intragastric administration of 9-15 g/kg of ethanol per day over a 4-day period. A nonintoxicating dose of BD of 4 g/kg, p.o., administered after elimination of ethanol from the blood was effective against the tremulous and convulsive components in all animals for 1-5 hours. This period of time coincided with the time of		

DD FORM 1473

1 JAN 73

EDITION OF 1 NOV 65 IS OBSOLETE
S/N 0102-014-0001

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

034 700 AB

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE(When Data Entered)

20. **ABSTRACT (continued)**

maximum severity of the withdrawal syndrome as seen in the control animals. These results suggest that BD may be useful in the treatment of the ethanol withdrawal syndrome in man.

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE(When Data Entered)

PREFACE

The authors thank N. Whitley and R. Williams for their technical assistance.

ACQUISITION OF	
NTIS	Write Section ☒
ERIC	Soft Section ☐
UNCLASSIFIED	☐
JUSTIFICATION	
BY DISTRIBUTION/AVAILABILITY CODES	
Dist.	AD/AL ABC OF SPECIAL
A	

TABLE OF CONTENTS

	Page
Preface	1
Introduction	5
Methods	6
Results	7
Discussion	9
References	10

LIST OF FIGURES

Figure 1. Effect of 1,3-butanediol on the withdrawal score	7
Figure 2. Effect of 1,3-butanediol on naive rats	8

INTRODUCTION

The clinical management of ethanol withdrawal has to consider both acute and chronic aspects of ethanol intake. During the early stages of the withdrawal period, a subject displays signs of intoxication similar to those observed during the first drinking episode. As detoxication proceeds and the blood ethanol concentrations decline to approximately 100 mg/dl, a gradual transition develops from depression to hyperexcitability. With the total elimination of blood ethanol, a series of neurological signs and reactions emerge which include general agitation, tremors, convulsions, hallucinations and delirium tremens.^{11,24,32} In addition, a number of side effects resulting from long-term intoxication with heavy doses of ethanol are evident. These may include malnutrition, weight loss, a lessened resistance to infection, hepatitis, cirrhosis of the liver, various vitamin deficiencies, peripheral neuropathy and general, neurological, psychiatric and clinical deterioration.^{11,24,32} Thus, an ethanol withdrawal syndrome can be a serious medical problem and may be fatal if not properly managed. Therefore, the primary aim of treatment is to reduce the neuromuscular and autonomic hyperactivity, thereby preventing exhaustion so that necessary clinical management and treatment can proceed.³²

Empirically, any drug that will suppress nervous excitability may ameliorate the severity of the withdrawal reaction. To date a variety of compounds which are either structurally or pharmacologically similar to ethanol have been effective in treatment.³¹ Among these have included aliphatic alcohols and their corresponding aldehydes, paraldehyde, chloral hydrate, barbiturates, phenothiazines, and benzodiazepines.³¹ However, the optimal drug is not only efficacious in controlling the withdrawal syndrome, but is devoid of major side effects. Of the drugs just listed, some are either more toxic than ethanol or have severe side effects including their ability to induce dependence.^{1,13,31}

The availability of a number of animal models of ethanol dependence^{5,6,8-10,15,16,22,23,26,27,29,33,34} now allows the testing of a variety of potential chemotherapeutic agents for their ability to suppress the signs and

responses of the ethanol withdrawal syndrome. Utilizing the model of ethanol dependence in the rat recently developed in this laboratory,¹⁸⁻²⁰ a number of compounds were screened and found to be effective. Of these, 1,3-butanediol (BD), a compound of low toxicity^{2-4,7,25} suppresses a variety of signs and responses in rats characteristic of the ethanol withdrawal syndrome.

METHODS

Male Sprague-Dawley rats (200-300 g) (Caw:CFE(SD)) were rendered ethanol-dependent by intubation of a 20 percent solution of ethanol at 9-15 g/kg daily in up to six fractions over a 4-day period.¹⁸⁻²⁰ Since for the induction of ethanol dependence the maximum tolerable doses were used, about one-third of the animals usually died due to overdosage. On the day of withdrawal, the animals were observed at hourly intervals, initially for the disappearance of ethanol intoxication and then for the onset of an ethanol withdrawal syndrome. Blood samples were taken also at hourly intervals from the tail vein but starting with the onset of signs of the ethanol withdrawal syndrome. This continued until the complete clearance of ethanol from the blood. Blood ethanol levels were determined using an automated adaptation¹⁷ of a gas chromatographic method of Roach and Creaven.²⁸ At this point the animals were treated with BD (4 g/kg, p.o.) or untreated. The group to which a given animal was assigned was determined using a table of random numbers on a single blind basis, i.e., the experimenter doing the behavioral evaluations was unaware of which animals were treated with BD. Hourly evaluations continued until the disappearance of the overt signs of the withdrawal syndrome (Figure 1).

The onset of the withdrawal syndrome was based on visual and tactile evaluation of the intensity of the following signs: tremors of the tail, caudal region and head, general tremors, tail rigidity, general rigidity, hyperactivity and convulsions. For the scoring of BD's effectiveness in suppressing the withdrawal syndrome only the tremors were used. These were rated on a scale of 1, 2, or 3 and were classified into mild, moderate, and severe, respectively.¹⁸⁻²⁰ In general, the severity of tremors of the tail and caudal region

ranged from 1-3, whereas the maximum score of the head tremors usually was not higher than 2. The severity of the withdrawal is expressed as a total score which represents the sum of the individual scores assessed for four types of tremors observed at each observation session.

RESULTS

The withdrawal tremors usually lasted from 20-24 hours in animals that received no treatment (Figure 1). This period corresponds to the time from the onset of the withdrawal when ethanol was still present in the blood to the total disappearance of the overt signs and responses of the withdrawal syndrome. However, the period of withdrawal corresponding to the time when ethanol was




Figure 1. Effect of 1,3-butanediol (BD) (4 g/kg, p.o.) on the withdrawal score. The withdrawal score is defined in the text. ●—● refers to untreated ethanol-dependent rats. o----o refers to BD-treated, ethanol-dependent rats. Time zero corresponds to the point at which all ethanol has been eliminated from the blood, and for BD-treated animals denotes the point at which BD was administered. Numbers in parentheses denote the number of animals observed, while each point refers to the mean of the withdrawal scores. Statistical differences were found for the period 1-5 hours after BD treatment using the median test ($P < 0.05$).

still present in the blood was 4-6 hours. The maximum severity of the withdrawal reactions usually occurred when blood ethanol levels decreased to less than 100 mg/dl and up to 4 hours later.

Administration of single doses of BD reduced the severity of the withdrawal tremors for varying periods of time in different animals. In general, the score dropped to about zero in all treated animals and was statistically different from controls for 1-5 hours when compared using the median test ($P < 0.05$) (Figure 1). This period also coincided with the time of maximum severity of the withdrawal syndrome as seen in the controls. The tremors reappeared with a severity and time course of recovery similar to the untreated animals approximately 8 hours after administration of BD. Additionally, no convulsions were observed in any of the BD-treated animals.

The ability of acute doses of BD to induce intoxication was determined using behavioral parameters as described previously.¹⁸⁻²¹ Doses of 2-10 g/kg were administered orally to naive animals deprived of food overnight. Intoxication was observed in a dose-dependent manner (Figure 2). At the dose of 4 g/kg




Figure 2. Effect of 1,3-butanediol on naive rats. Each group contained four animals. The intoxication score was assigned as follows: 0 - normal; 1 - sedation; 2 - ataxia 1; 3 - ataxia 2; 4 - ataxia 3; 5 - loss of righting reflex; 6 - coma.¹⁸⁻²⁰

used for suppressing the ethanol withdrawal syndrome, no significant degree of intoxication was observed.

DISCUSSION

The results reported here indicate that BD effectively suppresses the tremulous and convulsive components of the ethanol withdrawal syndrome in the rat. This would suggest the possible use of this compound in treatment of some aspects of the human counterpart. Although serious consideration of clinical application is premature, BD has a number of positive attributes. In addition to being able to ameliorate withdrawal signs, it is nonintoxicating in the doses used (Figure 2).¹⁴ Some of its pharmacological and biological properties have been established during the last 30 years in studies using BD as a synthetic source of calories.³⁰ In general, BD is relatively nontoxic in both humans¹² and experimental animals,^{2-4,7,14,25} and has little or no toxic effects with doses used in this study. There have been no reports suggesting that long-term consumption of BD can induce physical dependence or intoxication. However, since in our experiment highly intoxicating amounts of ethanol are necessary to induce physical dependence, the possibility that BD could be addictive cannot be excluded.

Whether BD can be used in a clinical setting remains to be determined. Also, because of its structural similarity to ethanol, BD and other related compounds may be useful in exploring the specificity of alcohols in inducing physical dependence.

REFERENCES

1. Adriani, J. and Morton, R. C. Drug dependence: important considerations from the anesthesiologist's viewpoint. *Anesth. Analg. (Cleve.)* 47:472-482, 1968.
2. Bornman, G. Physiological properties of the glycols and their toxicity, 1. *Arzneim. Forsch.* 4:643, 1954.
3. Bornman, G. Physiological properties of the glycols and their toxicity, 2. *Arzneim. Forsch.* 4:710, 1954.
4. Bornman, G. Physiological properties of the glycols and their toxicity, 3. *Arzneim. Forsch.* 5:38, 1955.
5. Ellis, F. W. and Pick, J. R. Experimentally induced ethanol dependence in rhesus monkeys. *J. Pharmacol. Exp. Ther.* 175:88-93, 1970.
6. Essig, C. F. and Lam, R. C. Convulsions and hallucinatory behavior following alcohol withdrawal in the dog. *Arch. Neurol.* 18:626-632, 1968.
7. Fischer, L., Kopf, R., Loeser, A. and Meyer, G. Chemical structure and pharmacological effect of glycols, especially 1,3-butylene glycol. *Z. Gesamte Exp. Med.* 115:22, 1949.
8. Freund, G. Alcohol withdrawal syndrome in mice. *Arch. Neurol.* 21:315-320, 1969.
9. Goldstein, D. B. Rates of onset and decay of alcohol physical dependence in mice. *J. Pharmacol. Exp. Ther.* 190:377-383, 1974.
10. Goldstein, D. B. and Pal, N. Alcohol dependence produced in mice by inhalation of ethanol: grading the withdrawal reaction. *Science* 172:288-290, 1971.
11. Isbell, H., Fraser, H. F., Wikler, A., Belleville, R. E. and Eisenman, A. J. An experimental study of the etiology of "rum fits" and delirium tremens. *Q. J. Stud. Alcohol* 16:1-33, 1955.
12. Kies, C., Tobin, R. B., Fox, H. M. and Mehlman, M. A. Utilization of 1,3-butanediol and nonspecific nitrogen in human adults. *J. Nutr.* 103:1155-1163, 1973.
13. Knott, D. H. and Beard, J. D. A new approach to the treatment of acute withdrawal from alcohol. *Psychosomatics* 9:311-313, 1968.

14. Kremer, J. N., Vitolina, S. P., Frank, E. L., Baumann, V. R. and Schmidt, A. A. In: *Advances in Parenteral Nutrition*, Berg, E., editor, p. 170. Stuttgart, Georg Thieme Verlag, 1969.
15. Lester, D. Self-maintenance of intoxication in the rat. *Q. J. Stud. Alcohol* 22:223-231, 1961.
16. Lester, D. and Freed, E. X. Criteria for an animal model of alcoholism. *Pharmacol. Biochem. Behav.* 1:103-107, 1973.
17. Majchrowicz, E. Determination of ethanol, methanol and acetone in biological fluids by automated gas chromatography. *Am. Chem. Soc. Div. Biol. Chem.* 298 (Abstract), 1971.
18. Majchrowicz, E. Induction of physical dependence on alcohol and the associated metabolic and behavioral changes in rats. *Pharmacologist* 15: 159 (Abstract), 1973.
19. Majchrowicz, E. Spectrum and continuum of ethanol intoxication and withdrawal in rats. *Pharmacologist* 16:646 (Abstract), 1974.
20. Majchrowicz, E. Induction of physical dependence upon ethanol and the associated behavioral changes in rats. *Psychopharmacologia* 43:245-254, 1975.
21. Majchrowicz, E. and Hunt, W. A. Temporal relationship on the induction of tolerance and physical dependence after continuous intoxication with maximum tolerable doses of ethanol in rats. *Psychopharmacologia* (in press).
22. McQuarrie, D. G. and Fingle, E. Effects of single doses and chronic administration of ethanol on experimental seizures in mice. *J. Pharmacol. Exp. Ther.* 124:264-271, 1958.
23. Mello, N. K. A review of methods to induce alcohol addiction in animals. *Pharmacol. Biochem. Behav.* 1:89-101, 1973.
24. Mendelson, J. H., editor. *Experimentally induced chronic intoxication and withdrawal in alcoholics*. *Q. J. Stud. Alcohol* (Supplement No. 2), 1964.
25. Meyer, G. Comparative experiments on the influence of polyhydric alcohols on reproductive processes. *Fette Seifen* 53:88, 1951.

26. Pieper, W. A. and Skeen, M. J. Induction of physical dependence on ethanol in rhesus monkeys using oral acceptance technique. *Life Sci.* 11:989-997, 1972.
27. Pieper, W. A., Skeen, M. J., McClure, H. M. and Bourne, P. G. The chimpanzee as an animal model for investigating alcoholism. *Science* 176: 71-73, 1972.
28. Roach, M. K. and Creaven, P. J. A micromethod for the determination of acetaldehyde and ethanol in blood. *Clin. Chim. Acta* 21:275-278, 1968.
29. Roach, M. K., Khan, M. M., Coffman, R., Pennington, W. and Davis, D. L. Brain ($\text{Na}^+ + \text{K}^+$)-activated adenosine triphosphatase activity and neurotransmitter uptake in alcohol-dependent rats. *Brain Res.* 63:323-329, 1973.
30. Schussel, H. Sparing effect of polyhydric alcohols in nutrition, and some remarks on enlarging the basis of our nutrition. *Klin. Wochenschr.* 31: 768, 1953.
31. Victor, M. Treatment of alcoholic intoxication and the withdrawal syndrome. A critical analysis of the use of drugs and other forms of therapy. *Psychosom. Med.* 33:636-650, 1966.
32. Victor, M. and Adams, R. D. The effect of alcohol on the nervous system. *Res. Publ. Assoc. Res. Nerv. Ment. Dis.* 32:526-573, 1953.
33. Walker, D. W. and Zornetzer, S. F. Alcohol withdrawal in mice: electroencephalographic and behavioral correlates. *Electroencephalogr. Clin. Neurophysiol.* 36:233-244, 1974.
34. Wallgren, H., Kosunen, A. L. and Ahtee, L. Technique for producing an alcohol withdrawal syndrome in rats. *Isr. J. Med. Sci. (Supplement 9)*: 63-71, 1973.